41 results
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
25 Mar 24
Results of Operations and Financial Condition
7:03am
reduce the negative effects of retinal inflammation without the associated potential side effects of systemic anti-inflammatory drugs or chronic steroid
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
12 Feb 24
Regulation FD Disclosure
5:23pm
and characterized by intraocular inflammation that is often chronic, can flare up at any time, and can lead to visual impairment and vision loss. Significant unmet … 1 Day 7 Chronic Posterior Uveitis (N=12) Day 14 Day 21 Cohort 2: 0.6 µg N=4 KIO-104-1101: Phase 1 Study Design Study Design Endpoints Key Results
8-K
EX-99.2
KPRX
Kiora Pharmaceuticals Inc
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
disorders affecting the uvea and characterized by intraocular inflammation that is often chronic, can flare up at any time, and can lead to visual
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
9 Nov 23
Regulation FD Disclosure
7:02am
that is o\en chronic, can flare up at any 9me, and can lead to visual impairment and vision loss. Significant unmet need for a steroid sparing approach …
32 Day 28 Cohort 1: 0.3 µg N=4 Day -14 to 0 Screening Cohort 3: 1.2 µg N=4 Day 1 Day 7 Chronic Posterior Uveitis (N=12) Day 14 Day 21 Cohort 2: 0.6
8-K
EX-99.1
l9ai53rr45s2l0l2j3
9 May 23
Kiora Pharmaceuticals Reports First Quarter Results; Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease Treatments
7:02am
424B3
u8mq1js8yeo3x6 pojk
28 Dec 22
Prospectus supplement
4:48pm
424B1
tejhzl
22 Jul 22
Prospectus with pricing info
6:00pm
FWP
gikm6rtx
14 Jul 22
Free writing prospectus
5:14pm
8-K
EX-99.1
q6rstzb
11 Jan 22
Regulation FD Disclosure
12:00am
8-K
EX-99.1
bsynk
14 Sep 21
Regulation FD Disclosure
4:20pm
8-K
EX-99.1
op7148tfq4g7ui3ro
27 May 21
Regulation FD Disclosure
7:01am
424B3
0ctafp3s6i2t4v7g
30 Apr 21
Prospectus supplement
5:01pm